Glioblastoma multiforme is the most prevalent and aggressive malignant tumor of the central nervous system. Currently available treatments do not have the desired impact and only marginally improve life expectancy. Glioblastoma multiforme has one of the highest unmet needs in oncology.
We have identified two compounds that specifically and selectively kill glioblastoma multiforme cells. Models have shown that tumors are regressing to the point where there is no tumor mass identifiable. These drugs are well tolerated in animal models and are expected to be well tolerated in humans.
In 2014, a combined 84,704 cases of glioblastoma multiform were diagnosed in France, Germany, Italy, Spain, UK, US and Japan. Glioblastoma multiforme is the 17th most common cancer and the second most common cancer in children. The majority of glioblastoma multiforme tumors are resistant to the frontline chemotherapeutic drug. There is no standard second line treatment.
We are collaborating with neurosurgeons, chemists, and international contract research organizations.
We are actively looking for partners and investors. If you are interested in working with us, or if you would like more information about our cause please contact us below.